Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Divests China JV Techpool
May 22, 2018
- Kyowa Kirin to Use Surrogate Endpoint in PIII Trial of Sakigake CKD Treatment; Application Could Come as Early as 2022
May 22, 2018
- AZ Files Forxiga for Expanded Use in Type 1 Diabetes in Japan
May 22, 2018
- Ethical Drug Sales Up 0.2% in FY2017: Crecon Report
May 21, 2018
- Dustin Haines Named as President of ViiV Healthcare Japan
May 21, 2018
- Growject to Enter PIII Study for SHOX Deficiency: JCR
May 21, 2018
- Kyowa Kirin’s Burosumab Hits Primary Endpoint in Multinational PIII Study in XLH Children including Japan
May 21, 2018
- Nobelpharma Becomes Medipal’s Equity Method Affiliate
May 21, 2018
- Talion Authorized Generics Rack Up 1.5 Billion Yen in Single Month
May 18, 2018
- Fujifilm’s Cancer Peptide Vaccine Flops in Japan PIII
May 18, 2018
- Sawai Seeks Strategical Alliance, Intra-Industry Network under New Midterm Biz Plan
May 18, 2018
- 10 Major Japan Drug Makers’ Sales Up 3.3%, but Decline Expected for FY2018 on Price Revision
May 18, 2018
- Alecensa Approved for 1st-Line Treatment of NSCLC in Taiwan: Chugai
May 17, 2018
- Daiichi Sankyo, Canadian Biotech Expand Joint Research on Bispecific Antibodies
May 16, 2018
- Gilead Seeks Japan Approval for Epclusa
May 16, 2018
- Towa Aims at Expansion into US and ASEAN Markets, Annual Sales of 100 Billion Yen under New 3-Year Plan
May 16, 2018
- Nichi-Iko, Eisai to Copromote Partner’s Generics from October
May 16, 2018
- Eisai Poised to Focus on Maximization of Lenvima Value: CEO
May 16, 2018
- Eisai Chalks Up 1st Double-Digit Growth in 11 Years on Merck Deal, Global Brands
May 16, 2018
- Taisho to Launch Voluntary Redundancy Program
May 15, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…